Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
M6620 + Irinotecan for Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial is studying the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with metastatic solid tumors. M6620 and irinotecan hydrochloride may stop the growth of tumor cells.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service